深圳扬厉医药

VyBio Therapeutics (Yangli Pharmaceutical) is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of innovative small molecule and siRNA-based therapies. Founded in 2018, the company focuses on addressing significant unmet medical needs in oncology and chronic diseases, including hypertension and metabolic disorders. VyBio's lead candidates include TFX06, a next-generation selective estrogen receptor degrader (SERD) in Phase 3 trials for breast cancer, and VB19055, a highly selective aldosterone synthase inhibitor for uncontrolled hypertension. The company operates multiple R&D centers across China and maintains a GMP-compliant manufacturing facility in Zhengzhou. Backed by prominent investors like Qiming Venture Partners and TF Capital, VyBio aims to deliver "first-in-class" and "best-in-class" medicines to global markets.